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Abstract
Introduction:  Renal  cell  tumors  comprise  both  benign  --  oncocytoma  --  and  malignant  --  clear
cell renal  cell  carcinoma,  papillary  renal  cell  carcinoma,  and  chromophobe  renal  cell  carcinoma
-- entities. Since  the  differential  diagnosis  among  renal  cell  tumors  is  sometimes  difﬁcult  on
clinical, imaging  and  pathological  grounds,  and  prognosis  is  quite  dissimilar,  epigenetic-based
diagnostic biomarkers,  specially  promoter  methylation,  might  be  useful  for  accurate  diagnosis
and therapeutic  planning.
Materials  and  methods:  EpiTect  Methyl  II  PCR  Array  was  used  to  screen  methylation  status  of
22 genes,  involved  in  epithelial  to  mesenchymal  transition.  Quantitative  real-time  methylation
speciﬁc  polymerase  chain  reaction  was  performed  for  candidate  gene  validation,  and  methyl-
ation levels  of  renal  cell  tumors  subtypes  and  normal  kidney  were  determined  and  compared.
Results: MST1R  promoter  methylation  level  was  signiﬁcantly  higher  in  clear  cell  renal  cell
carcinoma (median:  5367)  compared  to  other  renal  cell  tumors  (median:  papillary  renal  cell
carcinoma  --  1084,  chromophobe  renal  cell  carcinoma  --  1023,  oncocytoma  --  1337)  and  normal
kidney (median:  1125),  allowing  for  accurate  discrimination  from  other  renal  cell  tumors  with
high sensitivity  (>96.7%)  and  speciﬁcity  (86.7%).∗ Corresponding author.
E-mail addresses: carmenjeronimo@ipoporto.min-saude.pt, cljeronimo@icbas.up.pt (C. Jerónimo).
♦ Joint senior authors.
ttp://dx.doi.org/10.1016/j.acup.2015.01.004
341-4022/© 2015 Associac¸ão Portuguesa de Urologia. Published by Elsevier España, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusion:  Quantitative  MST1R  promoter  methylation  may  be  useful  as  biomarker  for  accurate
diagnosis  of  clear  cell  renal  cell  carcinoma  in  problematic  cases.
© 2015  Associac¸ão  Portuguesa  de  Urologia.  Published  by  Elsevier  España,  S.L.U.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Metilac¸ão  do  gene  MST1R  como  biomarcador  de  diagnóstico  em  tumores  de  células
renais
Resumo
Introduc¸ão: Os  tumores  de  células  renais  englobam  neoplasias  benignas  --  oncocitoma  --  e  malig-
nas -- carcinoma  de  células  renais  de  tipo  célula  clara,  papilar  e  de  células  cromófobas.  Uma
vez que  o  diagnóstico  diferencial  entre  eles  não  é  linear  do  ponto  de  vista  clínico,  imagiológico
e patológico,  e  que  o  prognóstico  de  cada  subtipo  é  distinto,  o  desenvolvimento  de  biomar-
cadores de  diagnóstico  com  base  em  alterac¸ões  epigenéticas,  nomeadamente  a  metilac¸ão  do
promotor de  genes,  poderá  ser  útil  para  o  diagnóstico  e  planeamento  do  tratamento.
Material  e  métodos: A  presenc¸a  de  metilac¸ão  do  promotor  de  22  genes  envolvidos  na  transic¸ão
epitélio-mesênquima  foi  avaliada  através  da  plataforma  comercial  EpiTectMethylIIPCR  Array.  Os
resultados  foram  validados,  no  gene  candidato,  por  ‘‘polymerase  chain  reaction’’  quantitativo
em tempo  real  especíﬁco  para  metilac¸ão.  Os  níveis  de  metilac¸ão  de  cada  tipo  histológico  de
tumores de  células  renais  e  de  tecido  renal  normal  foram  calculados  e  comparados.
Resultados:  O  nível  de  metilac¸ão  do  promotor  do  gene  MST1R  foi  signiﬁcativamente  mais  ele-
vado nos  carcinomas  de  células  renais  de  tipo  célula  clara  (mediana:  5.367)  comparativamente
com carcinomas  de  células  renais  papilares  (mediana:  1.084),  carcinomas  de  células  renais  de
células cromófobas  (mediana:  1.023),  oncocitomas  (mediana:  1.337)  e  rim  normal  (mediana:
1.125), permitindo  identiﬁcar  carcinomas  de  células  renais  de  tipo  célula  clara  com  elevada
sensibilidade  (>  96,7%)  e  especiﬁcidade  (86,7%).
Conclusão:  O  nível  de  metilac¸ão  do  promotor  do  gene  MST1R  poderá  constituir  um  biomar-
cador útil  para  o  diagnóstico  de  carcinomas  de  células  renais  de  tipo  célula  clara  em  casos
problemáticos.
© 2015  Associac¸ão  Portuguesa  de  Urologia.  Publicado  por  Elsevier  España,  S.L.U.  Este
é um  artigo  Open  Access  sob  a  licença  de  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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aIntroduction
Renal  cancer  has  an  estimated  age-standardized  inci-
dence  and  mortality  rate  respectively  of  4.4/100,000  and
1.8/100,000  worldwide.1 In  Europe,  renal  cancer  incidence
ranks  seventh  and  eighth  among  all  non-cutaneous  malig-
nant  neoplasms,  and  in  North  America  kidney  and  renal
pelvis  cancers  account  for  65,150  estimated  new  cases  and
13,680  deaths  in  both  genders  in  2013,  with  men  being  more
affected  than  women.2 Besides  the  classical  presentation  as
metastatic  disease,  mostly  because  kidney  cancer  is  asymp-
tomatic  at  its  earliest  stages,  an  increasingly  higher  number
of  tumors  are  being  incidentally  discovered  as  small  masses,
frequently  posing  diagnostic  challenges  in  what  concerns  the
distinction  between  benign  and  malignant  tumors.3
Renal  cell  tumors  are  the  most  common  neoplasms  of  the
kidney  (80--85%),  followed  by  urothelial  carcinoma  of
the  renal  pelvis  (15--20%).4 Renal  cell  tumors  (RCTs)  are
heterogeneous  at  the  genetic,  morphological  and  clinical
levels,  comprising  both  benign  and  malignant  entities.5,6Underscoring  the  high  heterogeneity  of  RCT,  malignant
tumors  --  renal  cell  carcinomas  (RCC)  --  might  have  different
responses  to  novel  targeted  therapies.7 The  most  frequent
a
t
ialignant  RCT  is  clear  cell  renal  cell  carcinoma  (ccRCC),
ollowed  by  papillary  renal  cell  carcinoma  (pRCC)  and
hromophobe  renal  cell  carcinoma  (chRCC),  accounting
espectively  for  70%,  10--15%  and  5%  of  all  RCT.4 Onco-
ytoma,  the  most  common  benign  tumor,  accounts  for
pproximately  5%  of  all  RCT.5
Histological  subtyping  provides  relevant  prognostic  infor-
ation,  independent  from  tumor  pathological  stage  and
rade:  ccRCC  is  the  most  aggressive  subtype,  display-
ng  lower  cancer-speciﬁc  survival  than  pRCC  and  chRCC,
hereas  no  differences  in  cancer  speciﬁc  survival  are  appar-
nt  between  pRCC  and  chRCC.8,9
Usually,  information  on  histological  subtype  is  available
nly  after  pathological  evaluation  of  the  nephrectomy  spec-
men,  and  thus  this  valuable  diagnostic  and  prognostic  data
annot  be  taken  into  account  for  planning  the  best  time  for
urgery,  especially  in  cases  of  small  renal  tumors  (<4  cm)
hat  should  beneﬁt  from  nephron  sparing  therapy.3,10 For
hese  small  tumors,  limitations  of  imagiological  techniques
nd  core  biopsy  histopathological  examination  preclude
ccurate  characterization  of  some  lesions,  seriously  limiting
he  pre-operative  information  about  the  biological  behav-
or  of  the  tumor  available  for  the  urologist.3,10 Moreover,
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n  the  setting  of  active  surveillance  protocols,11,12 the
evelopment  of  novel  diagnostic  biomarkers,  preferentially
inimally-  or  non-invasive,  is  of  paramount  importance.
The  association  between  both  genetic  and  epige-
etic  alterations  and  renal  cancer  development  is  widely
cknowleged.4,13,14 Additionally,  speciﬁc  genetic  and/or  epi-
enetic  alterations  were  found  to  be  characteristic  of  cer-
ain  tumor  types,  and  therefore  may  act  as  speciﬁc  diagnos-
ic  biomarkers.13,14 Epigenetic  biomarkers,  such  as  methyl-
tion  status  of  a  gene  promoter  (promoter  hiperme-
hylation),  which  is  associated  with  repression  of  gene
xpression,  may  be  detected  in  the  patient’s  serum  or
rine.15,16 Thus,  it  may  constitute  important  pre-operative
on-invasive  diagnostic  tools  and/or  useful  ancillary  test  for
he  diagnosis  of  renal  masses  through  ﬁne  needle  aspira-
ion  cytology  or  tissue  biopsy,  allowing  for  the  discrimination
etween  benign  and  malignant  RCT  and/or  for  the  identiﬁ-
ation  of  more  aggressive  malignant  tumors.
Tumor  aggressiveness  in  the  form  of  local  invasion  and
cquisition  of  metastatic  potential  has  been  associated
ith  epithelial  to  mesenchymal  transition  (EMT).17 Key  EMT
ffectors  were  described  to  be  regulated  by  epigenetic
echanisms,18,19 and  EMT-related  genes  were  found  to  be
eregulated  in  renal  cell  tumors.14 Thus,  epigenetic  dere-
ulation  of  cellular  pathways  involved  in  EMT  might  account
or  differences  in  RCT’s  aggressiveness,  and  provide  useful
iagnostic  and  prognostic  biomarkers.
Therefore,  we  aimed  to  systematically  evaluate  the
ethylation  status  of  EMT-related  genes  in  the  four  most
requent  RCT  subtypes  and  investigate  their  potential  use
s  clinically  relevant  diagnostic  and  prognostic  tools.
ethodsatients,  sample  collection  and  DNA  extraction
umor  tissue  from  120  total  or  partial  nephrectomy  speci-
ens  performed  between  2003  and  2007  (30  of  each  ccRCC,
i
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igure  1  Renal  cell  tumors  (RCTs)  morphology:  (a)  clear  cell  ren
pRCC), (c)  chromophome  renal  cell  carcinoma  (chRCC)  and  (d)  oncoA.S.  Pires-Luís  et  al.
RCC,  chRCC  and  oncocytoma)  (Fig.  1),  and  morphologically
ormal  kidney  (cortical)  tissue  from  9  nephrectomy  speci-
ens  for  upper  urinary  tract  neoplasia  and  12  renal  biopsies
erformed  in  the  diagnostic  work-up  of  renal  dysfunction
without  neoplasia  or  inﬂammation),  were  included  in  this
tudy.  All  procedures  were  performed  at  the  Portuguese
ncology  Institute  --  Porto  (Portugal),  after  informed  con-
ent  was  obtained.
Tumor  tissue  samples  were  obtained  immediately  after
urgery  and  snap-frozen.  Renal  biopsies  were  frozen  as  part
f  the  routine  protocol.  All  samples  were  stored  at  −80 ◦C
nd  subsequently  cut  in  a  cryostat.  The  presence  and  extent
f  tumor  were  evaluated  by  H&E  stains,  to  ensure  at  least
0%  of  tumor  in  the  samples.
Genomic  DNA  was  extracted  as  previously  described.20
rieﬂy,  DNA  was  digested  overnight  with  proteinase  K
20  mg/mL)  in  the  presence  of  10%  SDS  at  55 ◦C,  extracted
ith  phenolchloroform  and  precipitated  with  100%  ethanol.
Tumor  classiﬁcation  (WHO),  grading  (Fuhrman)  and  stag-
ng  (TNM)  were  routinely  assessed  for  all  tumor  cases  in
ormalin-ﬁxed  parafﬁn-embedded  tissue.5,21
Relevant  clinical  data  were  collected  from  clinical  charts.
his  study  was  approved  by  the  Institutional  Review  Board
Comissão  de  Ética  para  a  Saúde)  of  Portuguese  Oncology
nstitute  -- Porto,  Portugal  (CES518/2010).
piTect  Methyl  II  qPCR  array
he  EpiTect  Methyl  II  PCR  Array  (SABiosciences,  Qiagen,
rederick,  MD,  USA)  was  used  as  a screening  method  to  eval-
ate  the  promoter  methylation  status  of  EMT-related  genes
n  20  samples  (4  ccRCC;  4  pRCC;  6  chRCC;  6  oncocytoma).
he  EMT  commercial  assay  (cat.  no.  524EAHS-901ZA-24)
ncludes  22  genes:  CDH1, CTNNAL1,  DSC2, DSP, EPCAM,
AB1, KRT19, KRT7, MAP3K5,  MST1R, NID2, OCLN, PLEK2,
LSCR1,  PPPDE2,  PTP4A1,  RGS2, SEH1L, SMAD4,  TGIF1,
SPAN13  and  YES1.
al  cell  carcinoma  (ccRCC),  (b)  papillary  renal  cell  carcinoma
cytoma  (hematoxylin  and  eosin  staining  200×).
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Assays  were  performed  according  to  the  manufacturer’s
instructions.  Brieﬂy,  equal  amounts  of  genomic  DNA  were
incubated  overnight  at  37 ◦C  with  a  DNA  methylation-
sensitive  restriction  enzyme,  which  digests  unmethylated
DNA;  with  a  DNA  methylation-dependent  restriction  enzyme
that  digests  methylated  DNA;  with  both  enzymes;  and
without  enzyme  added/‘‘mock’’  (Methyl-Proﬁler  DNA  Meth-
ylation  Enzyme  Kit,  SABiosciences).  The  enzyme  was
inactivated  at  65 ◦C  for  20  min  and,  after  digestion,  the
remaining  DNA  was  quantiﬁed  by  real-time  PCR  using  pre-
designed  primers  to  the  promoter  region.  DNA  ampliﬁcation
was  carried  on  a  7000  Sequence  Detection  System  (Applied
Biosystems,  Foster  City,  CA,  USA),  at  95 ◦C  for  10  min  fol-
lowed  by  40  cycles  of  97 ◦C  for  15  s  and  72 ◦C  for  1  min.
PCR  product  was  marked  with  SYBR® Green  and  Ct  val-
ues  were  obtained.  The  analysis  was  performed  using  a
SABiosciences  Excel-Based  Data  Analysis  Template,  and  the
percent  of  hypermethylated  DNA  was  obtained  by  compar-
ing  the  amount  of  DNA  in  each  digest  with  that  of  a  mock
digest,  representing  the  fraction  of  input  DNA  containing  at
least  two  methylated  CpG  sites  in  the  targeted  gene  region.
Bisulﬁte  treatment
Sodium  bisulﬁte  converts  unmethylated  cytosine  residues  to
uracil,  whereas  methylated  cytosine  residues  remained  as
such.  It  was  performed  with  EZ  DNA  Methylation-Gold  Kit
(Zymo  Research),  according  to  the  manufacturer’s  instruc-
tions,  in  a  total  of  120  tumor  samples  and  21  morphologically
normal  kidney  tissues,  as  mentioned  above.
Quantitative  MSP
Quantitative  real-time  polymerase  chain  reaction  (qMSP)
was  performed  for  all  the  tested  samples  after  DNA  bisulﬁte
treatment.
Primers  were  designed  to  amplify  methylated  bisulﬁte
converted  complementary  sequences  of  MST1R  promoter
using  Methyl  Primer  Express  v  1.0  (Applied  Biosys-
tems,  Foster  City,  CA,  USA).  Primer  sequences  used
for  Macrophage-stimulating-1  receptor  (MST1R)  [GenBank:
NM  002447]  were  5′GCGAGGATTGGTAGTGTTC3′ (forward)
and  5′TTCTATCGCCCTCGTAAATC3′ (reverse).  A  reference
gene  (-actin) was  used  to  normalize  for  DNA  input  in  each
sample.
QMSP  analysis  was  performed  using  an  7500  Real-time
PCR  system  (Applied  Biosystems,  Foster  City,  CA,  USA),  in  a
reaction  volume  of  20  L  consisting  of  10  L  of  SYBR® Green
PCR  Master  Mix  (Applied  Biosystems,  Foster  City,  CA,  USA),
7  L of  H2O,  0.5  L  of  forward  primer,  0.5  L of  reverse
primer  and  2  L  of  bisulfate-modiﬁed  DNA.  Each  sample  was
run  in  triplicate  and  ‘‘no  template  controls’’  were  included
in  each  plate  as  a  control  for  contamination.  A  calibration
curve  to  quantify  the  amount  of  fully  methylated  alleles  in
each  reaction  was  constructed  with  serial  dilutions  (1:5)  of
bisulﬁte  converted  universally  methylated  DNA  at  all  CpGs
(CpGenome  Universal  Methylated  DNA;  Millipore,  Billerica,
MA).  The  ampliﬁcation  reaction  was  carried  out  at  95 ◦C  for
2  min  followed  by  50  cycles  of  95 ◦C  for  15  s and  anneal-
ing  temperature  (60 ◦C)  for  1  min,  followed  by  melting  curve
analysis.
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Relative  levels  of  methylated  promoter  DNA  in  each  sam-
le  were  determined  by  dividing  the  mean  quantity  obtained
y  qMSP  analysis  for  each  gene  for  the  respective  value  of
he  internal  reference  gene  (ACTB).  This  value  was  multi-
lied  by  1000  for  easy  tabulation  (methylation  level  =  target
ene/reference  gene  ×  1000).
tatistical  analysis
he  frequency  of  methylated  samples  was  determined  for
he  all  four  RCT  types,  considering  the  highest  value  deter-
ined  in  the  normal  kidney  tissue  as  the  cutoff.  Both
edian  and  interquartile  ranges  of  methylation  levels  were
lso  determined.  Differences  in  methylation  levels  among
CT  subtypes  were  analyzed  using  Kruskal--Wallis  non-
arametric  ANOVA  followed  by  Mann--Whitney  U  test,  when
ppropriate.  p  values  in  multiple  comparisons  were  adjusted
ccording  to  the  Bonferroni  method.  Statistical  signiﬁcance
evel  was  set  at  p  <  0.05  (two-sided).  Disease  speciﬁc  sur-
ival  and  disease  free  survival  curves  (Kaplan--Meier  with
og-rank  test)  were  computed  for  histological  subtype  and
ST1R  promoter  methylation  levels.  Statistical  analysis  was
erformed  using  IBM® SPSS® Statistics  for  Windows,  version
2.0  (SPSS,  Chicago,  IL,  USA).
esults
romoter  methylation  screening  with  EpiTect
ethyl II  PCR  Array
ive  out  of  the  22  EMT-related  genes  tested  --  CDH1, DSC2,
RT7,  MST1R  and  TSPAN13  --  displayed  hypermethylation
t  the  respective  promoter  regions.  Among  these,  MST1R
epicted  the  highest  percent  of  hypermethylated  DNA  --
90%  --  meaning  that  at  least  two  CpG  sites  in  the  targeted
ene  region  were  methylated  in  more  than  90%  of  input  DNA
ample.  Thus,  MST1R  promoter  metylation  was  chosen  for
ubsequent  validation.
ST1R  promoter  methylation  analysis  by  qMSP
elevant  clinical  and  pathological  data  of  the  120  tumors
ncluded  in  this  study  are  depicted  in  Table  1. No  statistically
igniﬁcant  associations  between  MST1R  promoter  methyl-
tion  levels  and  pathological  stage  were  found  (p  =  0.06).
owever,  MST1R  methylation  levels  of  Fuhrman  grade  3
umors  (median:  1451;  range:  401--12,367)  were  higher
han  those  with  Fuhrman  grade  4  (median:  938,  range:
18--7085),  and  this  difference  attained  statistical  signiﬁ-
ance  (p  =  0.011).
To  categorize  samples  as  methylated  or  unmethylated,
 cutoff  value  was  chosen  based  on  the  highest  methyla-
ion  ratio  value  obtained  for  the  respective  normal/control
amples,  ensuring  perfect  speciﬁcity  of  the  assay.  We  found
hat  in  ccRCC  the  methylation  frequency  was  60%  and,
n  the  remaining  histological  subtypes,  methylation  fre-
uency  was  very  low  (1%)  in  pRCC,  and  absent  in  chRCC  and
ncocytoma.  The  most  aggressive  RCC  subtype,  ccRCC,  dis-
layed  higher  MST1R  methylation  levels  compared  to  pRCC,
hRCC  and  oncocytomas  (Table  2),  and  this  was  statistically
68  A.S.  Pires-Luís  et  al.
Table  1  Clinical  and  pathological  features  of  patients
included  in  this  study.
Renal  cell
tumors
Normal
kidney
Number  of  patients,  n  120  21
Age at  diagnosis,  median
(range)
60  (29--83)  60  (19--83)
Gender,  n  (%)
Male  70  (58.3)  11  (52.4)
Female  50  (41.7)  10  (47.6)
Pathological  stage,  n  (%) n.a.
pT1  46  (38.4)
pT2  19  (15.8)
pT3  25  (20.8)
pT4  --
n.a.  (oncocytoma)  30  (25.0)
Fuhrman  grade,  n  (%) n.a.
1 3  (2.5)
2 28  (23.3)
3 43  (35.9)
4 16  (13.3)
n.a.  (oncocytoma) 30  (25.0)
s
s
T
t
a
r
i
9
Table  3  Comparison  of  the  distribution  of  MST1R  meth-
ylation  levels  among  renal  cell  tumor  subtypes  and  normal
kidney.
p  value*
ccRCC  pRCC  chRCC  Oncocytoma
Normal  kidney  <0.001  0.108  0.066  0.716
Oncocytoma  <0.001  0.128  0.001  --
chRCC <0.001  0.535  --  --
pRCC <0.001 -- --  --
* Mann--Whitney test, Bonferroni’s correction (statistically sig-
niﬁcant when p < 0.01). ccRCC, clear cell renal cell carcinoma;
pRCC, papillary renal cell carcinoma; chRCC, chromophobe renal
cell carcinoma; n.s., not signiﬁcant.
Table  4  Validity  estimates  for  MST1R  promoter  methyla-
tion level  in  different  settings.
%  ccRCC  vs. chRCC  vs.
pRCC  chRCC  Oncocytoma  Oncocytoma
Sensitivity  96.7  100  100  96.7
Speciﬁcity  86.7  86.7  86.7  53.3
PPV 87.9  88.2  88.2  67.4
NPV 96.3  100  100  94.1
Accuracy  91.7  93.3  93.3  75
w
vn.a., not applicable.
igniﬁcant  (Table  3).  MST1R  methylation  levels  of  chRCC  also
igniﬁcantly  differed  from  those  of  oncocytoma  (p  =  0.008,
able  3).
MST1R  methylation  levels  allowed  for  the  discrimina-
ion  between  ccRCC  and  the  remainder  RCT  --  pRCC,  chRCC
nd  oncocytoma  --  with  high  sensitivity  (96.7%,  100%,  100%,
espectively)  and  speciﬁcity  (86.7%  for  the  three  compar-
sons),  as  well  as  between  chRCC  and  oncocytoma,  with
6.7%  sensitivity  and  53.3%  speciﬁcity  (Table  4).
Table  2  MST1R  methylation  levels  and  frequencies  among
normal  kidney  tissues  and  different  renal  cell  tumor
subtypes.
Methylation
levela
median
(range)
Methylation
frequencyb
(%)
ccRCC  5367  (530--12368)  18/30  (60%)
pRCC 1084  (0--7085)  1/30  (3%)
chRCC 1023  (524--1701)  0/30  (0%)
Oncocytoma  1337  (805--2139)  0/30  (0%)
Normal  kidney  1125  (627--4917)  0/21  (0%)
ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell
carcinoma; chRCC, chromophobe renal cell carcinoma.
a Methylation level = target gene (MST1R) quantity
mean/reference gene (ACTB) quantity mean × 1000.
b A sample is considered methylated when its methylation level
is higher than the highest methylation level in normal/control
samples (4917). Methylation frequency = number of samples
methylated/total of samples, for each histological subtype and
normal kidney.
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nPPV, positive predictive value; NPV, negative predictive value;
ccRCC, clear cell renal cell carcinoma; pRCC, papillary renal cell
carcinoma; chRCC, chromophobe renal cell carcinoma.
MST1R  promoter  methylation  levels  did  not  associate
ith  cancer-speciﬁc  survival  (p  =  0.21)  nor  disease-free  sur-
ival  (p  =  0.091).
iscussion
acrophage-stimulating-1  receptor  (MST1R),  also  known
s  Ron  (Recepteur  d’Origine  Nantais)  is  a  receptor  tyro-
ine  kinase,  member  of  the  MET  proto-oncogene  family.
ST1R  binds  macrophage  stimulating  protein  (MSP)  and
s  found  in  macrophages,  epithelial  cells,  osteoclasts  and
ematopoietic  cells.22--24 In  normal  epithelial  cells,  MST1R
s  involved  not  only  in  cell  proliferation  and  survival
inhibition  of  apoptosis)  but  also  in  integrin-dependent
ell  adhesion  and  motility.22--24 MSP/MST1R  signaling  dere-
ulation  was  found  in  cancer  cells,25--27 and  MST1R
ltered  expression  was  reported  in  several  human  neo-
lasms,  including  hepatocellular,28 breast,29 colon,30 lung,31
varian,32 nasopharyngeal33 and  bladder34 cancer,  but  not  in
enal  cancer.  Several  oncogenic  MST1R  variants  have  been
escribed,25--27 and  hypermethylation  of  a  speciﬁc  region  of
ST1R  promoter  was  reported  to  be  associated  with  the
ranscription  of  an  oncogenic  MST1R  variant,35 but  MST1R
romoter  methylation  had  not  been  previously  described  in
CTs.
In  this  study,  we  showed  that  quantitative  MST1R  pro-
oter  methylation  is  a  common  feature  of  ccRCC,  and  its
evels  are  signiﬁcantly  higher  than  those  observed  in  pRCC,
hRCC,  oncocytoma  and  normal  renal  tissue,  suggesting
ot  only  a  role  in  renal  tumorigenesis  but  also  a  speciﬁc
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RMST1R  methylation  in  renal  cell  tumors’  diagnosis  
implication  in  the  genesis  of  the  clear  cell  type.  Further-
more,  the  distribution  of  MST1R  promoter  methylation  levels
allowed  for  accurate  discrimination  of  ccRCC  from  other
RCT,  a  ﬁnding  that  is  of  particular  diagnostic  relevance.  It
had  been  previously  reported  that  the  promoter  methyla-
tion  level  of  a  panel  of  three  genes  --  CDH1, PTGS2  and
RASSF1A  --  could  discriminate  the  four  main  histological
types  of  RCT,  although  with  limited  sensitivity.36 Thus,  either
alone  or  in  conjunction  with  that  gene  panel,  MST1R  pro-
moter  methylation  might  provide  a  useful  ancillary  tool  for
the  histopathological  or  cytopathological  evaluation  of  sus-
picious  renal  masses.
Although  previous  studies  on  RCT  identiﬁed  promoter
hypermethylation  of  several  genes37,38 using  genome-wide
promoter  methylation  analysis,  data  validation  in  an  inde-
pendent  clinical  series  of  samples  is  mostly  lacking,
impairing  the  evaluation  of  its  usefulness  as  diagnostic
biomarkers.  On  the  other  hand,  most  studies  are  focused
in  ccRCC,  the  most  common  RCT  subtype,  but  increasing
attention  must  be  paid  to  diagnostic  biomarkers  which  allow
for  the  discrimination  among  RCTs,  especially  chRCC  and
oncocytoma,  as  diagnosis  carries  quite  different  prognosis
and,  eventually,  therapeutic  options.  Global  methylation
proﬁles  of  chRCC  and  oncocytoma  have  been  published,39
but  again  without  validation  in  independent  set  of  clinical
samples.  Although  MST1R  promoter  methylation  surfaced  in
the  array  as  promising  biomarker,  we  further  extended  our
analysis  to  primary  RCT  and  normal  kidney  tissues,  to  assess
its  potential  clinical  usefulness.  Furthermore,  this  analysis
allowed  for  the  estimation  of  the  sensitivity  and  speciﬁcity
of  this  novel  epigenetic-based  biomarker,  which  depicted
high  diagnostic  performance.  However,  because  it  does  not
allow  for  the  coverage  of  all  relevant  differential  diagnos-
tic  problems  in  RCT,  the  integration  with  other  biomarkers,
such  as  the  microRNA  that  we  recently  demonstrated  to
distinguish  among  RCT  subtypes,40 might  be  relevant,  espe-
cially  in  the  setting  of  patient  selection  for  surveillance
protocols.  Importantly,  these  molecular  techniques  might  be
performed  in  clinical  samples  obtained  by  non-  or  minimally-
invasive  procedures,  such  as  urine  or  serum,16 or  serve  as
ancillary  tools  for  ﬁne  needle  aspiration  cytology  (FNAC),  as
previously  shown.40
This  study  was  performed  in  tumor  tissue  after  nephrec-
tomy,  which  limits  the  scope  of  this  new  diagnostic
biomarker.  Further  validation  of  MST1R  promoter  meth-
ylation  in  urine  and/or  serum  samples  is  warranted.
Additionally,  at  present,  the  precise  role  of  MST1R  promoter
methylation  in  ccRCC  carcinogenesis  is  not  known,  nor  is  its
relevance  for  the  development  of  non-ccRCC.  Elucidation  of
the  biological  role  of  MST1R  in  renal  carcinogenesis  might
allow  for  the  development  of  novel  therapeutic  strategies,
as  tyrosine  kinase  inhibitors  that  act  on  MST1R  might  modu-
late  its  effects  on  neoplastic  cells.41,42
Conclusions
MST1R  methylation  levels  might  be  a  useful  diagnostic
biomarker,  allowing  for  the  discrimination  of  ccRCC  from
other  RCT  and  normal  renal  tissue,  with  high  sensitivity
and  speciﬁcity.  Further  studies  are  warranted  to  indepen-
dently  assess  MST1R  promoter  methylation  level  as  a new
169
iagnostic  biomarker  for  RCTs,  and  also  to  illuminate  the
ole  of  MST1R  promoter  methylation  in  renal  carcinogenesis.
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